This is a phase I/II open label combination therapy study in two parts separated by at least eight weeks. In Part 1, HIV-infected infants and children will receive therapy with saquinavir plus two nucleoside antiretroviral agents chosen by the investigator and patient (or guardian). In Part 2, HIV-infected infants and children will receive therapy with saquinavir, nelfinavir and nucleoside antiretroviral agent(s) as chosen by the investigator and patient (or guardian). At least four patients (two each in Parts 1 and 2) will be enrolled in each of three age strata: six months to two years; greater than two years to six years; and greater than six years to 13 years. Each patient will receive therapy for at least 24 weeks. Clinical and laboratory pharmacokinetic, safety, virologic, and immunologic evaluations will be performed every four weeks for the first 16 weeks and then every eight weeks until week 72. Pharmacokinetic studies will be done at day 0, day 1, every four weeks until week 24, and at week 72 in patients who are willing and able to take both the adult and pediatric formulations, and patients who take only one formulation will have pharmacokinetic studies done at day 0, every four weeks until week 24, and at week 72. Saquinavir dosing may be adjusted based on the results of initial pharmacokinetic studies. Any patient in Part 1 who does not achieve acceptable saquinavir levels after dose adjustment will be given the opportunity to further modify dose and/or dose interval, or add nelfinavir to the original regimen at week eight.

Project Start
1997-12-01
Project End
1998-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
34
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Hunsaker, Sanita L; Garland, Beth H; Rofey, Dana et al. (2018) A Multisite 2-Year Follow Up of Psychopathology Prevalence, Predictors, and Correlates Among Adolescents Who Did or Did Not Undergo Weight Loss Surgery. J Adolesc Health 63:142-150
Lanzieri, Tatiana M; Chung, Winnie; Leung, Jessica et al. (2018) Hearing Trajectory in Children with Congenital Cytomegalovirus Infection. Otolaryngol Head Neck Surg 158:736-744
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139
Michalsky, Marc P; Inge, Thomas H; Jenkins, Todd M et al. (2018) Cardiovascular Risk Factors After Adolescent Bariatric Surgery. Pediatrics 141:
Lau, Chantal (2018) Breastfeeding Challenges and the Preterm Mother-Infant Dyad: A Conceptual Model. Breastfeed Med 13:8-17
El-Hattab, Ayman W; Zarante, Ana Maria; Almannai, Mohammed et al. (2017) Therapies for mitochondrial diseases and current clinical trials. Mol Genet Metab 122:1-9
Jin, Haoxing Douglas; Demmler-Harrison, Gail J; Coats, David K et al. (2017) Long-term Visual and Ocular Sequelae in Patients With Congenital Cytomegalovirus Infection. Pediatr Infect Dis J 36:877-882
Oh, Sam S; Du, Randal; Zeiger, Andrew M et al. (2017) Breastfeeding associated with higher lung function in African American youths with asthma. J Asthma 54:856-865
Bansal, N; Hampe, C S; Rodriguez, L et al. (2017) DPD epitope-specific glutamic acid decarboxylase (GAD)65 autoantibodies in children with Type 1 diabetes. Diabet Med 34:641-646
Zeller, Meg H; Washington, Gia A; Mitchell, James E et al. (2017) Alcohol use risk in adolescents 2 years after bariatric surgery. Surg Obes Relat Dis 13:85-94

Showing the most recent 10 out of 459 publications